Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1261 to 1275 of 2042 results for guidelines

  1. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  2. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment (HTE6)

    Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies...

  3. Bimekizumab for treating moderate to severe plaque psoriasis (TA723)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.

  4. Permanent His-bundle pacemaker implantation for treating heart failure (IPG694)

    Evidence-based recommendations on permanent His-bundle pacemaker implantation for treating heart failure. This involves attaching a wire connected to a pacemaker to the heart’s electrical conduction pathway (through a vein).

  5. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  6. Patient Status Engine for wireless monitoring of vital signs (MIB271)

    NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .

  7. Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults (IPG693)

    Evidence-based recommendations on deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults. This involves implanting an electrode in the brain and an electrical stimulator under the skin on the chest.

  8. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

  9. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

  10. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

  11. Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)

    Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.

  12. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

  13. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

  14. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

  15. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

    Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.